Bispecific antibodies (bsAbs) can simultaneously bind two different antigens via distinct antigen binding sites, enabling a wide variety of applications and benefits. Since bsAbs can target two distinct disease-associated antigens, they can provide access to novel therapeutic targets not available to traditional monoclonal antibodies (mAbs). In addition, the presence of multiple antigen binding sites allows for increased targeting precision and increased therapeutic potency compared to traditional mAbs, whilst also contributing to a reduction in the development of clinical resistance to antibody-based therapeutics.
Despite their benefits, bsAbs can be challenging to generate. One of the most commonly reported issues with bsAb production concerns heavy chain (HC) and light chain (LC) mispairing. In this technical note, we describe how Lonza’s bYlok® technology ensures high levels of accurate HC-LC pairing without detriment to critical quality attributes such as titer, binding affinity, stability, and immunogenicity.